Overview

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Status:
Recruiting

Trial end date:
2023-11-21

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab anlone in Japanese participants with NHL., or tafasitimab in combination with lenalidomide in in Japanese participants with R/R DLBCL, or tafasitimab in combination with parsaclisib in in Japanese participants with R/R DLBCL or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBCL.

Phase:

Phase 1

Details

Lead Sponsor:

Incyte Biosciences Japan GK

Treatments:

Lenalidomide